anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Extracellular vesicles (EVs) have garnered considerable attention among researchers as candidates for natural drug delivery systems. This study aimed to investigate whether extracellular vesicle mediated targeting delivery of growth differentiation factor-15 (GDF15) improves myocardial repair by reprogramming macrophages post myocardial injury.
METHODS: EVs were isolated from macrophages transfected with GDF15 (EXO-GDF15) and control macrophages (EXO-NC). In vitro and vivo experiments, we compared their reprogram ability of macrophages and regeneration activity. Furthermore, proteomic analysis were employed to determine the specific mechanism by which GDF15 repairs the myocardium.
RESULTS: Compared with EXO-NC, EXO-GDF15 significantly regulated macrophage phenotypic shift, inhibited cardiomyocyte apoptosis, and enhanced endothelial cell angiogenesis. Moreover, EXO-GDF15 also significantly regulated macrophage heterogeneity and inflammatory cytokines, reduced fibrotic area, and enhanced cardiac function in infarcted rats. Proteomic analysis revealed a decrease in fatty acid-binding protein 4 (FABP4) protein expression following treatment with EXO-GDF15. Mechanistically, the reprogramming of macrophages by EXO-GDF15 is accomplished through the activation of Smad2/3 phosphorylation, which subsequently inhibits the production of FABP4.
CONCLUSIONS: Extracellular vesicle mediated targeting delivery of growth differentiation factor-15 improves myocardial repair by reprogramming macrophages post myocardial injury via down-regulating the expression of FABP4. EXO-GDF15 may serve as a promising approach of immunotherapy.
Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
OBJECTIVE: This study aimed to analyse the influence of improved antenatal detection on the course, contemporary outcomes, and mortality risk factors of the complete atrioventricular block during fetal-neonatal and childhood periods in South Wales.
METHODS: The clinical characteristics and outcomes of complete atrioventricular block in patients without structural heart disease at the University Hospital of Wales from January 1966 to April 2021 were studied. Patients were divided into two groups according to their age at diagnosis: I-fetal-neonatal and II-childhood. Contemporary outcomes during the post-2001 era were compared with historical data preceding fetal service development and hence earlier detection.
RESULTS: There were 64 patients: 26 were identified in the fetal-neonatal period and the remaining 38 in the childhood period. Maternal antibodies/systemic lupus erythematosus disease (anti-Ro/Sjögren's-syndrome-related Antigen A and/or anti-La/Sjögren's-syndrome-related Antigen B) were present in 15 (57.7%) of the fetal-neonatal. Fetal/neonatal and early diagnosis increased after 2001 with an incidence of 1:25000 pregnancies. Pacemaker implantation was required in 34 patients, of whom 13 were diagnosed in the fetal-neonatal group. Survival rates in cases identified before 2001 were at 96.3% (26/27), whereas it was 83.8% (31/37) in patients diagnosed after 2001 (P > 0.05). Other mortality risk factors comprised a lower gestational week at birth, maternal antibodies, and an average ventricular heart rate of < 55 bpm.
CONCLUSIONS: Fetal diagnosis of complete atrioventricular block is still portends high fetal and neonatal mortality and morbidity despite significantly improved antenatal detection after 2001. Pacemaker intervention is needed earlier in the fetal-neonatal group. Whether routine antenatal medical treatment might alter this outcome calls for further prospective multicentre studies.
Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
PURPOSE: To obtain an oral composition containing peroxyacetic acid and effective in whitening tooth and removing stain of tooth. CONSTITUTION: This oral composition contains 0.01-5wt.% peroxyacetic acid therein. Peroxyacetic acid can be generated in situ by mixing a peroxide source (e.g. sodium peroxyborate) and a peroxyacid precursor (e.g. tetraacetylethylenediamine) into the composition. The peroxide source exist in a concentration of 0.5-30wt.% in the composition and the peroxyacid precursor exists in a concentration of 0.1-30wt.% therein. The composition is preferably prepared in a form of rinse, gel or paste and routinely used to bring about the above effect.
The present invention relates to chemicals fields, and in particular to a kind of resveratrol nanometer alcohol plastid and the preparation method and application thereof dissolves in ethyl alcohol the preparation method is as follows: S1. weighs soybean lecithin, stabilizer, resveratrol；S2. the mixed solution of step S1 is stirred into 1 ~ 5min under 30 ~ 35 DEG C of water bath conditions with the revolving speed of 800 ~ 1500r/min；S3. the solution after step S2 stirring is sealed, then with the distilled water that 60 ~ 80mL is added；S4. the mixed liquor of step S3 is stirred into 2 ~ 8min again with the revolving speed of 800 ~ 1500r/min；S5. by the liquid of step S4 under condition of ice bath 2.2 ~ 2.5min of ultrasound；S6. it filters to obtain the final product.The present invention has the characteristics that encapsulation rate is high, stability is more preferable using the resveratrol nanometer alcohol plastid that compound sucrose ester, Tween-80 stabilizer obtain.
PURPOSE:An immobilized germicide, obtained by immobilizing a specific compound in a polysaccharide subjected to specific treatment as a substrate, slightly liberating a drug from the polysaccharide, capable of exhibiting improved germicidal efficacy against Gram-positive and Gram-negative bacteria and useful in laboratories, etc. CONSTITUTION:An immobilized germicide obtained by treating the surface of a substrate consisting of a polysaccharide, e.g. cellulose, beta-cyclodextrin, dextrin, dextran or starch, with a silane coupling agent of a primary or secondary amine, e.g. gamma-aminopropyltriethoxysilane, and condensing the treated substrate with a compound, having at least phenolic OH group and capable of leaving the phenolic group even after reaction with the above-mentioned coupling agent, e.g. p-hydroxybenzyl alcohol, in the presence of palladium black as a catalyst in N2 atmosphere through dehydration. EFFECT:The residual property of the drug can be reduced and continuous sterilization can be carried out. Materials can be treated in a large amount by simple sterilizing operation, etc.
This study on the Effect of Oculo-Motor Exercises on Dynamic Visual Acuity, Balance and Performance in Volleyball Players was ethically approved by the "Istanbul Medipol University Non-Invasive Ethics Committee" with file number 10840098-604.01.01-E.14171 on 16.04.2020. The study included 52 female volleyball players aged 16-26 who played participants for at least 3 years without interruption. Power analysis was performed using the 3.1.9.5 version of the G-Power program to determine the number of individuals to be included in the study. Type-1 was accepted as 0.05 and power ratio as 80%. Effect size 0.8 was taken. According to the results of the power analysis, the number of participants required to be included in the study was determined as 52.

Participants; Age, height, weight, gender, body mass index, dominant side, position played in volleyball, number of weekly training, daily training time, previous sports injuries, education status, smoking and alcohol use, accompanying illnesses were questioned. FBT and YBT were used for balance evaluations, and Nelson's Hand Reaction Test was used for reaction times. In addition, Dynamic Visual Acuity and Vertical Jumping distances were evaluated twice before and after treatment.

Participants included in the study, the control group continued their routine ball training after the evaluations, while the intervention group continued with the oculo-motor training for 4 weeks, 6 days a week, in the morning and evening, for 10 minutes, 2 times a day, in addition to normal ball training. they did the exercises. While doing the exercises, individuals were taught to focus on the purpose they held in their hands, move their head, and aim fast enough to see the image clearly. Two repetitions each week were added to the exercise numbers. Ten seconds rest between two sets and five seconds rest between movements.
This study will be divided into two cohorts, by age, with separate study designs. The first cohort will include children 9 through 11 months of age. The second cohort will comprise children 15 through 23 months of age. The purpose of this detailed evaluation of safety and immunogenicity is to assess the reactogenicity of the vaccine and the immune responses to Vi-TCV. Serum specimens will be collected from all participants on study day 0 (before vaccination) and on post-vaccination study day 28 to quantify anti-Vi and anti-tetanus toxoid antibodies. All children will have an additional 0.5 mL of blood collected on study day 0 before study vaccination to test for the presence of malaria parasitemia at baseline.

Children 9 through 11 months of age in the Ouagadougou study area will be eligible for the first age cohort, which will be a double-blind, individually randomized, controlled trial. Up to 100 children in this cohort will be randomized in a 1:1 ratio to receive Vi-TCV (Group 1) or IPV (Group 2). Participants will be unaware of which study vaccine, Vi-TCV or IPV, is received. Vi-TCV or IPV will be administered with measles-rubella vaccine (MR) and YFV, as per Burkina Faso Expanded Programme on Immunization (EPI) schedule. These 9 through 11-month-old children will have immunogenicity to Vi-TCV, YFV, and tetanus toxoid assessed on study days 0 and 28.

Children 15 through 23 months of age in the Ouagadougou study area will be eligible for the second cohort, a randomized study of the safety and immunogenicity of Vi-TCV when co-administered with routine Expanded Programme on Immunisation (EPI) vaccines (MAV and MR) or given alone, and MAV immunogenicity when co-adminstered or given alone. Participants in this cohort (up to 150) will be randomized 1:1:1 to one of three treatment groups, as follows. The first group of participants (Group A) will receive Vi-TCV and IPV at study day 0, with a subsequent dose of MAV at study day 28; the second group of participants (Group B) will receive MAV and Vi-TCV at study day 0; the third group (Group C) will receive MAV and IPV at study day 0. All children will receive MR at study day 0. Cohort 1 will be unblinded on day 28 for safety and follow-up and to ensure MAV receipt in Group A. These 15 through 23-month-old children will have antibody to meningococcal A vaccine, anti-Vi antibody, and tetanus toxoid antibody assessed on study days 0 and 28.

Participants in both cohorts will have home or clinic visits on days 3 and 7 following vaccination for solicitation of local and systemic adverse events. Non-serious adverse events will be assessed up until the study day 28 visit. Serious adverse events will be captured throughout study follow-up and actively during the study day 180 visit.
Participants from the Experimental Group 1 will engage in a self-conversation through embodied perspective taking (body swapping), according to which they will be embodied alternately in their own virtual representation and in their counsellor's virtual body. They will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.
This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety of ABI-M201 and its effects on disease activity measures in men and women with mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist of 2 sequential, non-overlapping participant cohorts, separated by intervening interim analysis (IA). Both cohorts will involve 8-weeks of study drug treatment. Interim data from the initial treatment cohort (Cohort A) will inform decision to advance to the subsequent second cohort (Cohort B) and its dose selection. 20 subjects will be randomized to cohort A (1:1 allocation) and receive treatment with 1 capsule per day of ABI-M201 versus Placebo. 24 subjects will be randomized to cohort B (3:1 allocation) and receive treatment with up to 5 capsules one time a day of ABI-M201 versus Placebo.
Tong-Fu-Xing-Shen herbal formula prescription (0.4g\*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
The introduction of fundamental hygiene protocols within the healthcare sector during the nineteenth century led to a significant reduction in mortality rates. Contemporary advancements, such as alcohol-based sanitizers, have further enhanced hand hygiene practices. However, these measures are often overlooked in nursing facilities, resulting in low staff compliance rates and increased cross-infection rates. Novel approaches, such as cold plasma hand disinfection, present promising alternatives due to their minimal skin damage and economic benefits. This study aims to compare the disinfectant efficacy of cold plasma aerosol under practical application conditions with an alcoholic hand disinfectant listed by the Association for Applied Hygiene. The microbial count on participants' hands was measured, with particular attention paid to the spontaneous occurrence of fecal indicators and the presence of potentially infectious bacteria. A t-test for independent samples was conducted to determine whether there was a significant difference between the two cohorts regarding the research question. Statistical analysis revealed that the mean log colony-forming unit (CFU) values were significantly lower in the test cohort using only the cold plasma method for hand disinfection compared to the cohort using conventional alcohol-based hand disinfection. Moreover, it was demonstrated that, unlike alcohol-based hand disinfection, cold plasma application ensures the effective elimination of Staphylococcus aureus. The findings indicate that staff utilizing plasma disinfection have an average bacterial count that is 0.65 log units lower than those who regularly use alcohol-based hand disinfection. In addition to the efficacy of cold plasma disinfection, its superiority over alcohol-based hand disinfection was also established. Beyond offering economic and logistical advantages, cold plasma disinfection provides additional health benefits as it does not induce skin damage, unlike alcohol-based hand disinfection.
The largest mammalian organ, skin, consisting of a dermal connective tissue layer that underlies and supports the epidermis, acts as a protective barrier that excludes external pathogens and disseminates sensory signals emanating from the local microenvironment. Dermal connective tissue is comprised of a collagen-rich extracellular matrix (ECM) that is produced by connective tissue fibroblasts resident within the dermis. When wounded, a tissue repair program is induced whereby fibroblasts, in response to alterations in the microenvironment, produce new ECM components, resulting in the formation of a scar. Failure to terminate the normal tissue repair program causes fibrotic conditions including: hypertrophic scars, keloids, and the systemic autoimmune connective tissue disease scleroderma (systemic sclerosis, SSc). Histological and single-cell RNA sequencing (scRNAseq) studies have revealed that fibroblasts are heterogeneous and highly plastic. Understanding how this diversity contributes to dermal homeostasis, wounding, fibrosis, and cancer may ultimately result in novel anti-fibrotic therapies and personalized medicine. This review summarizes studies supporting this concept.
Maternal and child health has garnered considerable attention recently. The effects of prenatal exposure to PM2.5 and its components on thyroid function in both mothers and fetuses, as well as on offspring birth weight, remain unexplored. This study involved 446 mother-infant pairs from a cohort study in Ma'anshan, China, during 2021-2022. Air pollution data were obtained from the Tracking Air Pollution (TAP) project. Thyroid hormone levels (FT3, FT4, and TSH) were measured in maternal blood samples taken at various pregnancy stages and in cord blood. We employed multiple analytical methods to evaluate the effects of PM2.5 and its components on maternal thyroid function and birth weight z-score (BWz). The GLR analysis reveals that the effect of PM2.5 and its components on BWz differs according to the pregnancy stage and the specific pollutant involved. During the late pregnancy, increased exposure to PM2.5 and specific components (for instance,  NO 3 _   and SO 4 2 -   ) was correlated with elevated maternal FT4 levels (p < 0.05) and reduced BWz (p < 0.05). QgC results illustrated a notable negative correlation between heightened PM2.5 exposure and BWz in late pregnancy. BKMR analysis confirmed that overall exposure to PM2.5 and its components negatively impacted BWz during the third trimester. Mediation analysis showed that changes in maternal FT4 levels accounted for approximately 8.52%, 8.05%, and 8.13% of the negative effects on BWz from exposure to NH 4 +  , NO 3 _  and SO 4 2 -   , respectively (p < 0.05). In healthy pregnancies, exposure to PM2.5 and its components during the late pregnancy is linked to alterations in maternal thyroid hormone levels, potentially leading to reduced birth weight. Maternal FT4 levels may mediate the connection between PM2.5 components exposure and reduced the weight of offspring.
NEW MATERIAL:A peptide having a binding ability to an anti-AChR antibody in which a T cell recognition site and a B cell recognition site in an alpha-subunit of an acetylcholine receptor are linked through a tetrapeptide expressed by the formula. USE:A treating agent and diagnostic agent for myasthenia gravis. PREPARATION:For example, PAM resin is used as a solid-phase support according to a solid-phase synthetic method, and an amino acid having protected '-amino group and functional group in the side chain is linked from the C- terminal side thereto. The '-amino protecting group is subsequently removed and protected amino acids are successively linked according to an amino acid sequence of a peptide to synthesize a peptide chain on the resin. The resultant peptide chain is then subjected to deprotection and removal of the peptide from the solid phase in an HF reactor. The resultant peptide is subsequently purified by high performance liquid chromatography to afford the objective peptide having binding ability to an anti-AChR antibody.
In controlled clinical trials [see Clinical Studies (14)] a total of 77 (7%) of the 1102 Insulin Degludec-treated patients with type 1 diabetes were 65 years or older and 9 (1%) were 75 years or older. A total of 670 (25%) of the 2713 Insulin Degludec-treated patients with type 2 diabetes were 65 years or older and 80 (3%) were 75 years or older. Differences in safety or effectiveness were not suggested in subgroup analyses comparing subjects older than 65 years to younger subjects. 

In the safety outcomes trial (DEVOTE), a total of 1983 (52%) of the 3818 Insulin Degludec-treated patients with type 2 diabetes were 65 years or older and 381 (10%) were 75 years or older. Differences in safety or effectiveness were not observed in these subgroup analyses. 

Nevertheless, greater caution should be exercised when Insulin Degludec is administered to geriatric patients since greater sensitivity of some older individuals to the effects of Insulin Degludec cannot be ruled out. The initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia. Hypoglycemia may be more difficult to recognize in the geriatric patients.
Synaptic dysfunction plays a key role in Parkinson's disease (PD), and plasma extracellular vesicle (EV) synaptic proteins are emerging as biomarkers for neurodegenerative diseases. Assessment of plasma EV synaptic proteins for their efficacy as biomarkers in PD and their relationship with disease progression was conducted. In total, 144 participants were enrolled, including 101 people with PD (PwP) and 43 healthy controls (HCs). The changes in plasma EV synaptic protein levels between baseline and 1-year follow-up did not differ significantly in both PwP and HCs. In PwP, the changes in plasma EV synaptic protein levels were significantly associated with the changes in Unified Parkinson's Disease Rating Scale (UPDRS)-II and III scores. Moreover, PwP with elevated levels (first quartile) of any one plasma EV synaptic proteins (synaptosome-associated protein 25, growth-associated protein 43 or synaptotagmin-1) had significantly greater disease progression in UPDRS-II score and the postural instability and gait disturbance subscore in UPDRS-III than did the other PwP after adjustment for age, sex, and disease duration. The promising potential of plasma EV synaptic proteins as clinical biomarkers of disease progression in PD was suggested. However, a longer follow-up period is warranted to confirm their role as prognostic biomarkers.
<P>PROBLEM TO BE SOLVED: To provide a soap bar which contains a microorganismic culture having no alkali resistance and is capable of preventing the microorganismic culture from deadening in the soap bar, furthermore capable of securely exerting the operation the microorganismic culture has, and to provide a method of delivery using the same.  <P>SOLUTION: This soap bar has the microorganismic culture having no alkali resistance, a gelatin layer covering the microorganismic culture, and a soap body circumscribing the gelatin layer. The microorganism preferably contains at least lactic acid bacteria. Preferably, a layer material in which the microorganismic culture is laminated between a pair of gelatin layers may be arranged so as to divide the soap body into at least two pieces. By this method for delivery utilizing the soap bar, that is a method for delivering a microorganism onto the surface of the person, the microorganism is delivered in an active condition onto the surface of the person.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A lyophilized antibody panel is disclosed for interrogation using elemental analysis. The antibody panel includes multiple antibodies each element-tagged or element-labelled with one or more isotopes such that each different antibody is isotopically distinguishable from the other antibodies. Each element tag can include one or more unique isotopes or unique combinations of isotopes. The set of element-tagged antibodies can be lyophilized in admixture. Thus, the lyophilized element-tagged antibody panel can be easily and efficiently resuspended and mixed with a sample prior to interrogation with an elemental analyzer, such as a mass spectrometer. This lyophilized element-tagged antibody panel can provide the benefits of an element-tagged assay while also being easy to use and remaining stable for long durations.